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Gastroesophageal reflux disease is one of the leading gastrointestinal disorders. Current treatments include lifestyle modifications,
pharmacological therapies, surgical fundoplications, and, more recently, endoscopic procedures. The rising concern of long-
term side effects of the popular proton-pump inhibitors and the more recent evidence raising doubts about the durability of
fundoplication have spurred reinterest in endoscopic procedures to treat reflux disorders. In the aftermath of several innovative
antireflux procedures that were introduced and failed clinically or financially over the past decade, there is lingering confusion
regarding the merits of the presently available interventions. This paper focuses on one endoscopic procedure, Stretta, which
now enjoys the longest experience, a recent meta-analysis, and robust data supporting its safety, efficacy, and durability. Stretta
reduces esophageal acid exposure, decreases the frequency of transient lower esophageal relaxation, increases patient satisfaction,
decreases medication use, and improves quality of life. As such, this procedure remains a valuable nonsurgical treatment option in
the management of gastroesophageal reflux disease.
1. The Burden of Gastroesophageal
Reflux Disease
Gastroesophageal reflux disease (GERD) is themost common
digestive disorder affecting one third of the population
worldwide and resulting in 4 to 5 million physician visits
annually. It results primarily from the loss of an effective
antireflux barrier against the retrograde movement of gastric
contents into the distal esophagus. The average incremental
cost in the United States to an employer for an employee
with GERD in 2007 was estimated to be $ 3,355 per year
includingmedical costs, prescription drug costs, and indirect
costs such as absenteeism and disability [1]. Furthermore,
a significant financial burden on medical care comes from
hospital admissions due to acid-induced noncardiac chest
pain. Uncontrolled GERD results in a significant reduction in
quality and productivity at work. GERD is also a risk factor
for esophageal adenocarcinoma that is becoming increasingly
prevalent and has the fastest rising incidence of any cancer
[2]. The current treatment for GERD consists of lifestyle
modifications, pharmacological therapies, endoscopic proce-
dures, and surgical interventions. The initial management of
GERD includes lifestyle modifications, such as elevating the
head of the bed, dietary modifications, restricting alcohol,
and managing obesity. Pharmacological management typi-
cally consists of the use of H2 blockers and, in most cases,
proton-pump inhibitors (PPIs). Although medical therapy
with PPIs is effective in most patients, there are increasing
concerns regarding the long-term use of these drugs. These
include interaction with a number of cardiac medications
such as clopidogrel [3], association with osteoporotic frac-
tures [4], hospital-acquired diarrhea and pneumonia, hypo-
magnesemia, and vitamin B12malabsorption [5]. In addition,
prolonged PPIs use has been associated with chronic atrophic
gastritis in patients infected with H. pylori [6]. In the recent
years, a significant number of patients with GERD are found
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to be refractory to PPIs therapy despite even twice daily use
of these drugs [7]. Surgical options for GERD also have their
limitations including increased costs, hospitalization, up to
10% complication rate, and 28-day recovery [8]. Furthermore,
the durability and side effects of fundoplication have fallen
short of expectations. Recent 5-year data from the LOTUS
trial suggests that 15%–20% of those who have undergone
fundoplication may have GERD symptoms [9].
2. Advent of Nonsurgical Antireflux Devices
Since the early 2000’s, several devices have been developed for
the endoscopic treatment of GERD, using approaches such as
sewing, transmural fasteners, endoscopic staplers, and ther-
mal treatment using radiofrequency energy. Other devices
involving injection, Enteryx (Boston Scientific, Boston, MA,
USA) or implantation of foreign materials, Gatekeeper reflux
repair system (Medtronic, Inc., Minneapolis, MN, USA)
at the esophageal junction are no longer used. Devices
that are currently commercially available for the endoscopic
treatment of GERD in the United States include the follow-
ing: EndoCinch (C. R. Bard, Inc., Murray Hill, NJ, USA);
EsophyX (EndoGastric Solutions, Redwood City, CA, USA);
Stretta (MederiTherapeutics, Greenwich, CT, USA); and SRS
Endoscope (Medigus,Omer, Israel).These are summarized in
Table 1.Of these, Stretta, which applies radiofrequency energy
to the lower esophageal sphincter (LES), has the longest
experience in the treatment of GERD.
3. What Is Stretta?
The Stretta procedure involves the application of controlled
radiofrequency (RF) energy to the LES region.Theprocedure,
approved by the Food andDrugAdministration in theUnited
States in 2000, uses a flexible catheter with a balloon-basket
assembly and nickel-titanium needle electrodes to deliver
the radiofrequency energy into the esophageal wall and LES
complex, while irrigating the overlying mucosa to prevent
heat injury. Figure 1 illustrates the established mechanisms of
action of Stretta.
Initial animal studies used porcine and canine models
and showed a thickening of the LES, decreased transient
lower esophageal relaxations (TLESRs), and decreased reflux
events [10].Multiple studies have demonstrated the safety and
efficacy of the Stretta procedure for GERD therapy. Some
studies had mixed results of its effectiveness and durability
[11]. Despite four randomized clinical trials, more than 60
prospective trials and more than 800 patients followed post-
Stretta procedure for 12 to 48 months, and there remain
unanswered questions, overstated myths, and underappre-
ciated realities about options in management of GERD.
Such questions include whether PPIs are truly effective and
safe, whether Stretta causes a stricture or neurolysis of the
LES, whether Stretta effectively decreases acid exposure and
improves symptoms and quality of life, and whether the
improvements are durable over time. In this paper we address
these questions and conclude that Stretta is a safe and effective
alternative to medical management or surgical management
in selected patients.
4. Myths about Stretta
4.1. Myth: Proton-Pump Inhibitors Effectively Control Symp-
toms in All Patients with GERD. PPIs comprise a class of
drugs widely used for the treatment of GERD. Their mecha-
nism of action involves inhibition of theH-KATPase enzyme
that is present in gastricmucosal parietal cells.This enzyme is
responsible for the secretion of hydrogen ions in exchange for
potassium in the gastric lumen, and its inhibition decreases
gastric acidity. First introduced in the late 1980’s, PPIs were
the most potent inhibitors of gastric acid secretion available,
with efficacy superior to histamine-2 receptor antagonists.
Because they effectively alleviate gastric-peptic symptoms
and facilitate healing of inflamed or ulcerated mucosa, cur-
rent guidelines recommend their use for the treatment of
GERD. PPIs are alsowell tolerated, with side effects occurring
at a rate of 1%–3% and with no significant differences among
the various agents. Such side effects most commonly include
headaches, nausea, abdominal pain, constipation, flatulence,
diarrhea, rash, and dizziness. However, over the past decade,
an increasing number of studies has shown that GERD
symptom control is not as optimal as originally thought
and marketed. A post hoc analysis of 5,794 patients from
four randomized double-blind studies revealed that partial
heartburn relief was experienced with the use of PPIs in
19.9% of patients with nonerosive reflux disease and in 14% of
patients with reflux esophagitis [7]. Another study reported
that only 61% of patients on PPIs with nonerosive esophageal
reflux disease experienced resolution of heartburn [12].
4.2. Myth: PPIs Use Is Safe. Over the past decade, sev-
eral potential adverse effects of long-term PPIs use had
generated great concerns: B12 deficiency; iron deficiency;
hypomagnesemia; increased susceptibility to pneumonia;
enteric infections; fractures; hypergastrinemia; and drug-
drug interactions [4]. This has led many patients with GERD
either to self-discontinue therapy resulting in symptomatic
recurrence or to solicit alternative methods to control their
symptoms. Miyamoto and colleagues followed a cohort of 44
patients over 5 years and found that only 77% had improve-
ment in their reflux symptoms [13]. Lundell and colleagues
followed a cohort of 53 patients randomized to PPIs versus
fundoplication; only 45% had continuous remission up to 12
years after randomization to the PPIs arm [14].
4.3. Myth: Fundoplication Effectively Controls Reflux Symp-
toms. Fundoplication as ameans of controllingGERD symp-
toms over a sustained period of time has shown poor results.
Lundell and colleagues followed a cohort of 144 patients for 7
years after fundoplication examining for recurrence of GERD
symptoms and the need to resume medical management of
reflux symptoms. They found that 34% had symptomatic
relapse, and many of them required medical management
[15]. Smith and colleagues followed a cohort of 1892 patients
for 10 years post fundoplication and found that 17% had
Gastroenterology Research and Practice 3












Stretta Conscious sedation $2000–3,500 per case 15,000 13 125 29
EsophyX General gnesthesia $7,000 per case 11,000 7 200 2
Medigus General anesthesia $3,200 per case >100 2 2 0
Linx General anesthesia $12,000 per case 1000 5 70 0
Figure 1: Stretta radiofrequency treatment mechanism of action
(with the permission of Mederi Therapeutics, copyright 2013).
resumed using antisecretory medications [16]. Spechler and
colleagues followed a cohort of 38 patients for 10 years after
fundoplication and found that 62% were using antisecretory
medications [17]. Oelschlager and colleagues followed a
cohort of 289 patients for 5 years and found that 61% of them
were taking some forms of antacid [18].
4.4. Myth: Stretta Causes Distal Esophageal Strictures.
Although the exact mechanism of action of Stretta in
relieving symptoms of acid reflux is unknown, one potential
mechanism is that it decreases the number of TLESRs
[19]. The latest theory suggests that this is accomplished
by a structural rearrangement of the smooth muscle and
redistribution of the interstitial cells of Cajal in the smooth
muscle of the LES [20]. Stretta was designed to minimize
damage to the esophagus. The four-channel radiofrequency
(RF) generator and catheter system delivers pure sine-wave
energy (465 kHz, 2 to 5watts per channel, and 80 volts
maximum at 100 to 800 ohms). Each needle tip incorporates
a thermocouple that automatically modulates power output
to maintain a desired target (muscle) tissue temperature.
Maintaining lesion temperatures below 50∘C minimizes
the collateral tissue damage due to vaporization and high
impedance values. Temperature is similarly monitored with a
thermocouple at each needle base, and power delivery ceases
if the mucosal temperature exceeds 50∘C or if impedance
exceeds 1000mOhms [19]. Maintaining tight temperature
control prevents mucosal damage to the distal esophagus
and gastroesophageal junction thus preventing stricture
formation. A recent double-blind sham-controlled study
of 22 patients showed that administration of sildenafil,
an esophageal smooth muscle relaxant, normalized the
gastroesophageal junction compliance to pre-Stretta levels,
arguing against GE junction fibrosis as an underlying
mechanism [19].
4.5. Myth: Stretta Causes Neurolysis in the Distal Esophagus.
DiBaise and colleagues followed a cohort of 18 patients
6 months after Stretta and found no adverse effects on
abdominal vagal function and no significant changes in any
esophageal motility parameter; however, a trend was noted
toward a reduction in the number of TLESRs induced by
gastric air distension (3.5/h versus 1.0/h; 𝑃 = 0.13). No
detrimental effects on peristalsis or swallow-induced LES
relaxation pressure were seen [21]. Arts and colleagues also
followed a cohort of 13 patients for 6 months after Stretta and
found that esophageal peristalsis (low-amplitude peristalsis
in the same three patients), resting LES pressure (18.2 ±
2.0mmHg; NS), and swallow-induced relaxations were not
significantly altered by the radiofrequency energy delivery
procedure, which also argues against the theory of neurolysis
[22].
4.6. Myth: Stretta Does Not Decrease Esophageal Acid Expo-
sure. Several studies have shown a decrease in esophageal
acid exposure after Stretta. Arts and colleagues followed a
cohort of 13 patients over 6 months, and all patients under-
went repeat pH monitoring 6 months after the procedure.
One measurement was technically inadequate and not inter-
pretable. In the evaluable patients, esophageal pHmonitoring
was significantly improved, from 11.6%±1.6% to 8.5%±1.8%
of the time at pH < 4 (𝑃 < 0.05) (Figure 2). Normalization
of the pH monitoring (<4% of the time at pH < 4) occurred
in only three patients. The DeMeester score showed a similar
improvement, from 46.8 ± 7.3 to 35.6 ± 6.7 (𝑃 = 0.01)
[21]. Aziz and colleagues showed similar results from their
prospective randomized sham study of 36 patients, which
showed significant reduction in esophageal acid exposure
[23]. Not all studies have come to the same conclusion.
DiBaise and colleagues followed a cohort of 18 patients after
Stretta for 6 months and found that there were no adverse
effects on vagal function and esophageal motility. There
were an improvement in symptoms, a decreased antacid
use, and decreased TLESRs, but no significant difference
in esophageal acid exposure [21]. Even though decrease in
acid exposure was not achieved in this study, Stretta did










Figure 2: Acid exposure (% pH < 4.0) before and after Stretta.
accomplish the primary goals of GERD treatment which are
to improve symptoms, improve quality of life, and decrease
medication use. Although this study did not show decreased
acid exposure, there are multiple other studies that did show
a decrease, and it is important to look at the entire body
of research showing, in many cases, improvement in acid
exposure.
The recently published meta-analysis by Perry and col-
leagues evaluated 18 studies and 1441 patients and showed
a significant reduction in esophageal acid exposure after
Stretta. Preprocedure and postprocedure esophageal pH
studies were documented in 11 of the 20 studies. The
DeMeester score improved from 44.37 ± 93 before Stretta
to 28.53 ± 33.4 after Stretta over an average period of 13.1
months in 267 patients across 7 studies (𝑃 = 0.0074).
The esophageal acid exposure was reported in 11 studies
comprising of 364 patients over a mean follow-up period
of 11.9 months. Esophageal acid exposure decreased from a
mean of 10.29% ± 17.8% to 6.51% ± 12.5% (𝑃 = 0.0003) [11].
4.7. Myth: Stretta Relieves GERD Symptoms by Placebo Effect.
Due to the lack of certainty around the mechanism by which
Stretta relieves GERD symptoms, there is a misconception
that Stretta works by placebo effect. Arts and colleagues
performed a double-blind sham-controlled study showing
that Stretta decreases LES compliance, which likely mitigates
inappropriate LES relaxations, the most common underlying
cause of GERD. This study also showed that there was a
significant improvement in symptoms as compared with
the patients who received the sham procedure [19]. Further
evidences that Stretta does not work by placebo effect are
the studies showing decreased esophageal acid exposure after
Stretta [22, 23]; see Table 2 for the summary of the myths
about Stretta.
5. Realities of Stretta
5.1. Reality: Stretta Improves Quality of Life and Patient
Satisfaction. There have been numerous studies showing that
patients treated with Stretta have a significant improvement
in quality of life. In the meta-analysis by Perry, 18 studies
containing 433 patients evaluated the effect of treatment on
patient quality of life (QoL) using the GERD-HRQL scale
with an average follow-up interval of 19.8 months. The QoL
scores improved from 26.11 ± 27.2 at baseline to 9.25 ± 23.7
after treatment (𝑃 = 0.0001). QoL scores were collected from
4 studies comprising 250 patients and were improved from
3.3 ± 5.9 to 4.97 ± 4.9 at a mean follow-up interval of 25.2
months (𝑃 = 0.001). SF-36 was utilized to assess global QoL
of the patient population in 6 studies. A total of 299 patients
responded to the SF-36 physical form, during a mean follow-
up period of 9.5 months, demonstrating an improvement
from 36.45 ± 51.6 at baseline to 46.12 ± 61.9 after procedure
(𝑃 = 0.0001). Two hundred sixty-four patients in 5 of the 6
studies responded to the SF-36 mental form demonstrating
improvement from 46.79 ± 20.5 to 55.16 ± 17.6 at 10-month
followup (𝑃 = 0.0015) [11] (Figure 3).
5.2. Reality: Stretta Decreases Acid Reflux Symptoms and
Medication Use. There have been several studies showing
a significant decrease in medication use after Stretta. Tri-
adafilopoulos and colleagues conducted a nonrandomized,
prospective, and multicenter study that included 118 patients
treated with Stretta for GERD. Follow-up information was
available for 94 patients (80%) at 12 months; the proportion
of patients requiring PPIs fell from 88% to 30%. There was
also an improvement in quality of life scores and reduction
in esophageal acid exposure [20]. In another trial by Liu and
colleagues of 90 patients with nonerosive or mildly erosive
disease, the onset of GERD symptom relief after Stretta was
less than two months in 70.0% and two-to-six months in
16.7%, while there was a significant improvement in GERD
symptoms and patient satisfaction (Figure 4). Medication
usage decreased significantly from 100% of patients on PPIs
therapy at baseline to 76.7% of patients showing elimination
of medication use or only as-needed use of antacids/H2-
receptor antagonists at 12 months [24]. Dughera and col-
leagues reported similar results in 48-month follow-up data
for 56 out of 69 patients who were treated with Stretta. RF
treatment significantly improved heartburn scores, GERD-
related quality of life scores, and general quality of life scores
at 24 and 48 months in 52 out of 56 patients (92.8%). At 48
months, 41 out of 56 patients (72.3%)were completely off PPIs
(Figure 5). Morbidity was minimal, except for one patient
who developed transient gastroparesis [25].
5.3. Reality: Stretta Is Safe. The recently published meta-
analysis by Perry revealed that the most common compli-
cations encountered after the Stretta procedure were gas-
troparesis and erosive esophagitis. These are known to be
transient and reversible. Early reports of esophageal perfo-
rations were attributed to operators’ inexperience, and no
such grave complications have been reported since then [10].
In a study of 77 patients who had the Stretta procedure,
none had esophageal perforation, dysphasia, or severe gas
bloating or stricture, documenting low complication rates
for mild fever (2/24:8%), pneumonia (1/24:4%), transient
dysphasia (3/24:12.5%), abdominal pain (2/24:8%) and 0%
mortality [26]. Complication rates compare favorably with
those of surgical interventions that appear to be around 4%,
for laparoscopic procedures and 9% for open fundoplications
[27]. There have been only 29 adverse events for more
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Table 2: Summary of myths and realities concerning GERD treatment.
Myths Realities
Proton-pump inhibitors effectively control symptoms
in all patients with GERD. Stretta improves quality of life and patient satisfaction.
Proton-pump inhibitor use is safe. Stretta decreases acid reflux symptoms and medicationuse.
Fundoplication effectively controls reflux symptoms. Stretta is not for every patient with GERD.
Stretta causes distal esophageal strictures. Stretta is safe.
Stretta causes neurolysis in the distal esophagus. Stretta is durable.
Stretta does not decrease esophageal acid exposure. Stretta improves gastric emptying.












Figure 3: Scores before and after Stretta.









Figure 4: Reflux symptoms 6 months after Stretta.
than 15,000 preformed procedures reported to the FDA
with the last being in 2005. There have been no adverse
events reported since the latest upgrades of the Stretta device
in 2005. The upgrades include more sensitive temperature
controls, easier user interface, and newer ablation prongs.
5.4. Reality: Stretta Is Durable. There have been several
long-term studies examining the durability of Stretta. One
of the longest follow-up studies has been that by Noar
and colleagues who showed that, in 109 patients with 48
months of followup, 75% of patients showed statistically
















Figure 5: PPI and antacid use 48 months after Stretta.
improvements in patient satisfaction and heartburn scores
[28]. Another study by Reymunde and colleagues followed a
cohort of 83 patients for 48months and found statistically sig-
nificant improvement in GERD symptom scores and GERD-
QoL scores, besides reporting that daily medication use was
needed by only 13.6%of patients at 48months, comparedwith
100% prior to treatment [29] (Figure 6). Recently, Dughera
reported on 56 patients who also reached 48 months of
followup and had significantly improved heartburn scores,
GERD-specific QoL scores, and general QoL scores at 24 and
48 months in 52 (93%) of patients. At 48 months, 41 patients
(72%) were completely off PPIs [25]. At 8 years, 60% of
available patientswere still not using PPIs [30].This compares
favorably with outcomes after fundoplication, showing that
nearly 60% undergoing surgery were back on PPIs after 8
years.
5.5. Reality: Stretta Improves Gastric Emptying. Growing
clinical evidence shows that delayed gastric emptying (gas-
troparesis) may be a factor associated with severe reflux,
dyspepsia, or both. Gastroparesis, concomitant in 25% of
patients with gastroesophageal reflux disease (GERD), has
been shown to improve after Stretta. Radiofrequency treat-
ment for GERD may potentially correct GERD-associated
gastroparesis and resultant reflux failures despite the twice
daily use of PPIs. Noar and colleagues showed that at 6
months after Stretta procedure gastric emptying scores had
improved significantly, with the percentage of solid food
emptied at 90 min improving from 41% to 66% (𝑃 < 0.0001)
and at 120min improving from 55% to 84%. Significant
improvements were seen at all time intervals. Overall, 23
6 Gastroenterology Research and Practice












Figure 6: Symptoms and quality of life after Stretta.
patients (74%) experienced normalization of gastric empty-
ing, and 4 patients improved but remained abnormal. Four
patients showed no improvement on their gastric emptying
scans, with one patient electing to undergo a Nissen pro-
cedure. All of the patients had a 1-year symptom follow-
up assessment, which showed significant improvements in
GERD-related quality of life, dyspepsia, and heartburn scores
[31].
5.6. Reality: Stretta Has Limitations. One of the limitations of
Stretta is that it has not proven to be cost effective. In a study
byComay et al., which followed a cohort of patients for 5 years
after being randomized to either once daily PPIs therapy,
fundoplication, or Stretta, this cohort was evaluated for
quality-adjusted life years, symptom-free months, and cost
effectiveness. Their results showed that the PPIs procedure
was the most cost effective strategy depending on the price
of omeprazole per pill. If the price of omeprazole was over
$2.00 per pill, then Stretta was deemed themost cost-effective
of the three strategies.The costs in this study were reported in
Canadian dollars and based on costs in the Canadian health
system.The estimated cost in this study of 5 years of PPIs use
was $2394.10, the cost of Stretta was $3,239.30, and the cost
of fundoplication was $7394.70 [32].There is great variability
in the cost of PPIs in the United States. At the time of this
publication, the average retail price per pill in one major
pharmacy chain was for $2.63 per pill omeprazole, for $4
per pill pantoprazole, and for $8.30 per pill esomeprazole.
The hidden cost the patient must also take into consideration
is the increasing number of side effects of PPIs that are
being reported and the increasing appreciation of treatment
failures [12]. Although Stretta has been associated with 29
complications in over 15,000 cases, including 5 esophageal
perforations early in its launch, no serious adverse events
have been experienced since the modified generator and
catheter in 2011 under Mederi Therapeutics were used.
Gastroparesis is a side effect of Stretta. Dughera and
colleagues found that only 1 out of 56 patients treated with
Stretta developed gastroparesis, and this resolved in 8 weeks
[25]. Noar and colleagues showed that Stretta improved
gastroparesis in a study where they followed a cohort of 31
patients with gastroparesis 6 months after Stretta and found
that 74% of patients have normalization of gastric emptying
[31]. There have been more frequent cases of postsurgical
gastroparesis that develops after surgical fundoplication for
GERD. It is estimated that 4% to 40% of patients who
undergo laparoscopic fundoplication develop intraoperative
vagal damage to some degree [33].
5.7. Reality: Stretta Is Not for Every Patient with GERD.
Stretta is ideal for patients with heartburn or regurgitation,
patients who have adequate esophageal peristalsis, who have
unsatisfactory GERD control with PPIs therapy, patients who
have 24-hour pH monitoring demonstrating pathologic acid
reflux, and patients who have nonerosive reflux disease or
grade A or B esophagitis.The patients who are not considered
good candidates for the Stretta procedure include those
patients with a greater than 2 cm long hiatal hernia, patients
who have significant dysphagia, patients who have grade C or
D esophagitis, and patients who have inadequate esophageal
peristalsis and incomplete LES relaxation with swallowing
[34]. Thus, careful patient selection is important to assure
benefit from this as well as other comparable procedures; see
Table 2 for the summary of the realities of Stretta.
6. Conclusions
In this paper, several randomized and prospective long-term
studies have been presented that address concerns about the
safety, tolerability, efficacy, and durability of Stretta that may
make Stretta a more desirable treatment option than chronic
PPI use or fundoplication in selected patients.
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